title: Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
abstract: BACKGROUND
  Salivary ductal carcinoma (SDC) is an uncommon malignant tumor of the salivary glands. Although there is no known standard of care for the treatment of advanced disease, the vast majority of patients with SDC may be offered palliative systemic therapy. We report a case of epidermal growth factor receptor 2 (HER2)-positive metastatic submandibular SDC with a complete and durable clinical response to treatment with trastuzumab in combination with chemotherapy.
  
  
  RESULTS
  A 62-year-old man was diagnosed with SDC of the left submandibular gland with extensive cervical lymph node involvement. The lesion was completely resected, and the patient underwent postoperative radiotherapy. After 6 months, multiple pulmonary metastatic lesions were detected. A complete response was reached with trastuzumab-based combination therapy, and no evidence of disease progression has been observed after 14 months of initiation of systemic therapy.
  
  
  CONCLUSIONS
  Trastuzumab-based combination therapies should be considered for advanced SDC.
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. prat.aleix@terra.es
authors.forename: Aleix
authors.initials: A
authors.lastname: Prat
authors.forename: Marta
authors.initials: M
authors.lastname: Parera
authors.forename: Vicky
authors.initials: V
authors.lastname: Reyes
authors.forename: Sergio
authors.initials: S
authors.lastname: Peralta
authors.forename: Susana
authors.initials: S
authors.lastname: Cedrés
authors.forename: Jordi
authors.initials: J
authors.lastname: Andreu
authors.forename: Pere
authors.initials: P
authors.lastname: Huguet
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: del Campo
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044584:Carcinoma, Ductal / Q000378:metabolism / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012468:Salivary Gland Neoplasms / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab